Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue

European Journal of Histochemistry

Volumn 57, Issue 2, 2013, Pages 80-82

  Salemi, Michele ^a   Galia, A ^b   Fraggetta, F ^b   La Corte, C ^b   Pepe, P ^b   La Vignera, S ^a   Improta, G ^c   Bosco, P ^d   Calogero, A E ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

^c REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^d OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Immunoistochemistry; PARP 1gene; Prostate cancer; Proteinexpression

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN;

AGED; APOPTOSIS; CARCINOMA; CELL NUCLEUS; CYTOPLASM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA; CELL NUCLEUS; CYTOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84892641981     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2013.e13     Document Type: Article

References (27)

1. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17: 37-47.
2. Kucuk O. Chemoprevention of prostate cancer. Cancer Metastasis Rev 2002;21: 111-24.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics CA. Cancer J Clin 2007;57:43-66.
4. Trojan L, Kiknavelidze K, Knoll T, Alken P, Michel MS. Prostate cancer therapy: standard management, new options and experimental approaches. Anticancer Res 2005;25: 551-61.
5. Walczak JR, and Carducci MA, Prostate cancer: a practical approach to current management of recurrent disease. Mayo. Clin Proc 2007; 82: 243-49.
6. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Death receptor-induced cell death in prostate cancer. J Cell Biochem 2004;91:70-9.
7. Zornig M, Hueber AO, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001;1551:F1-F37.
8. Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 2008;13:3046-82.
9. Hassa PO, Haenni SS, Elser M, Hottiger MO. Nuclear ADP-ribosylation reaction in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 2006;70:789-829.
10. Kim MY, Zhang T, Kraus WL. Poly(ADPribosyl) ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev 2005;19:951-67.
11. Burkle A. Poly(APD-ribosyl)ation, a DNA damage-driven protein modification and regulator of genomic instability. Cancer Lett 2001;163:1-5.
12. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28.
13. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Up-regulation of poly(ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010;8:812-21.
14. Eustermann S, Videler H, Yang JC, Cole PT, Gruszka D. The DNA-binding domain of human PARP-1 interacts with DNA single-strand breaks as a monomer through its second zinc finger. J Mol Biol 2011; 4071:49-170.
15. Sulzyc-Bielicka V, Domagala P, Hybiak J, Majewicz-Broda A, Safranow K, Domagala W. Colorectal cancers differ in respect of PARP-1 protein expression. Pol J Pathol 2012;63:87-92.
16. Klauschen F, von Winterfeld M, Stenzinger A, Sinn BV, Budczies J, Kamphues C, et al. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improbe survival in pancreatic cancer. Histopathology 2012;61:409-16.
17. Shimizu S, Nomura F, Tomonaga T, Sunaga M, Noda M, Ebara M, et al. Expression of poly(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance. Oncol Rep 2004;12:821-25.
18. Csete B, Lengyel Z, Kádár Z, Battyáni Z. Poly(adenosine diphosphate-ribose) polymerase-1 expression in cutaneous malignant melanomas as a new molecular marker of aggressive tumor. Pathol Oncol Res 2009;15:47-53.
19. Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F, et al. PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem 2012;56:e9.
20. Ro YK, Lee S, Jeong CW, Hong SK, Byun SS, Lee SE. Biochemical recurrence in Gleason score 7 prostate cancer in korean men: significance of the primary Gleason grade. Korean J Urol 2012;12:826-9.
21. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;1:228-42.
22. Salemi M, Calogero AE, Zaccarello G, Castiglione R, Cosentino A, Campagna C, et al. Expression of SPANX proteins in normal prostatic tissue and in prostate cancer. Eur J Histochem 2010;54:e41.
23. Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J. Notch/HES1-mediated PARP1 activation: a cell-type specific mechanism for tumor suppression. Blood 2011;117:2891-900.
24. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9:5370-9.
25. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009; 5:607-12.
26. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010;70:5457-64.
27. Ahmad M, Torky A, Glahn F, Scheubel RJ, Foth H. PARP-1 expression and activity in primary human lung cells. Arch Toxicol 2011;85:669-79.